EMA Authorised: Truqap (capivasertib) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Truqap (capivasertib) for breast cancer. Marketing authorization holder: AstraZeneca AB (decision date 18 September 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TRUQAP (CAPIVASERTIB)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: AstraZeneca AB. Decision date: 18/09/2025